Article
Oncology
Max S. Topp, Herbert Eradat, Axel Florschuetz, Andreas Hochhaus, Tomasz Wrobel, Jan Walewski, Wanda Knopinska-Posluszny, Abraham S. Kanate, Ewa Lech-Maranda, Uta Brunnberg, Surya Chitra, Tina G. Nielsen, Gila Sellam, Mahesh Shivhare, Izidore S. Lossos
Summary: This study evaluated the efficacy and safety of two anti-CD20-based triplet combinations for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. The results showed limited efficacy and safety issues with G-atezo-pola in patients with relapsed diffuse large B-cell lymphoma, indicating no further development is planned.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Cell Biology
Zizheng Wu, Qingpei Guan, Xue Han, Xianming Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Summary: A prognostic signature based on four immune-related genes was successfully constructed for predicting prognosis in DLBCL patients. The signature could classify patients into high- and low-risk groups with significantly different prognoses. Patients in the high-risk group showed significantly decreased activated memory CD4 T cells and activated dendritic cells, with lower immune scores.
Article
Biochemistry & Molecular Biology
Jin Roh, Hyo-Kyung Pak, Seongfeel Jeong, Sewon Hwang, Do Eon Kim, Hwal-Seok Choi, So-Jeong Kim, Hyunji Kim, Hyungwoo Cho, Joon Seong Park, Seong Hyun Jeong, Yoon Seok Choi, Jae Ho Han, Dok Hyun Yoon, Chan-Sik Park
Summary: DLBCL is a prevalent and aggressive non-Hodgkin's lymphoma. Increasing the expression levels of BCL2 family members may contribute to the development of new treatment strategies.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Jessica Rodrigues Placa, Arjan Diepstra, Tjitske Los, Matias Mendeville, Annika Seitz, Pieternella J. Lugtenburg, Josee Zijlstra, King Lam, Wilson Araujo da Silva Jr, Bauke Ylstra, Daphne de Jong, Anke van den Berg, Marcel Nijland
Summary: This study reproduced four gene expression signatures in DLBCL patients and validated three of them. In addition to the cell of origin, other signatures related to immune response and MYC activity were identified. These signatures capture different aspects of DLBCL biology and can co-occur in the same patient.
Review
Hematology
Wendan Xu, Philipp Berning, Georg Lenz
Summary: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous diagnostic category, with roughly one-third of patients not cured by standard treatments. BCR signaling and the PI3K pathway are proposed as potential targets for the treatment of DLBCL patients.
Article
Oncology
Tao Pan, Yizi He, Huan Chen, Junfei Pei, Yajun Li, Ruolan Zeng, Jiliang Xia, Yilang Zuo, Liping Qin, Siwei Chen, Ling Xiao, Hui Zhou
Summary: This study systematically investigated the tumor microenvironment and genetic factors associated with DLBCL to identify prognostic biomarkers. A seven-gene signature was established based on immune and stromal scores, showing critical prognostic value and independence in predicting DLBCL patient survival. The signature also demonstrated robust prognostic ability across different risk groups and was integrated into a nomogram for prognostic prediction.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Paola Chabay
Summary: EBV+ DLBCL, NOS is a new category with varying incidence rates among different populations, influencing tumor microenvironment and patient survival. EBV can alter genetic composition of tumor cells and affect recruitment of immune cells.
Article
Pathology
Ji Yuan, Hui Liu, Shimin Hu, Roberto N. Miranda, Xinjie Xu, Michael G. Bayerl, Cody J. Artymiuk, Holly Berg, Rebecca L. King, Min Shi, Rong He, David Viswanatha, L. Jeffrey Medeiros, Ellen D. Mcphail
Summary: This study reports 5 adult patients with FL and FL/DLBCL with concurrent BCL2 and IRF4 rearrangements. The clinicopathologic and mutational features of these patients are more akin to FL and DLBCL, and should not be characterized as large B-cell lymphoma with IRF4 rearrangement.
Article
Hematology
Shu-Yun Ma, Xiao-Peng Tian, Jun Cai, Ning Su, Yu Fang, Yu-Chen Zhang, Jin-Ni Wang, Robert Peter Gale, Qing-Qing Cai
Summary: A prognostic score for DLBCL patients based on infiltrating immune cells was constructed, showing that the immune risk score is an accurate and independent survival predictor in DLBCL patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
F. Montes de Jesus, Y. Yin, E. Mantzorou-Kyriaki, X. U. Kahle, R. J. de Haas, D. Yakar, A. W. J. M. Glaudemans, W. Noordzij, T. C. Kwee, M. Nijland
Summary: The study evaluated the use of radiomic features extracted from [F-18]FDG PET/CT using machine learning algorithms to discriminate FL from DLBCL. The Gradient Boosting classifier showed the best discrimination performance, surpassing the SUVmax-based logistic regression model.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Yi Chen, Luting Luo, Lushan Chen, Xiaoyun Zheng, Xiaozhu Yang, Zhihong Zheng, Jing Zheng, Tingbo Liu, Ting Yang, Jianda Hu
Summary: This study aimed to investigate the clinicopathological characteristics and prognosis of patients with co-existing FL and DLBCL components (FL/DLBCL). The results showed that patients with FL/DLBCL had intermediate clinical features between FL and DLBCL, and had inferior treatment response and survival compared to pure FL. However, when receiving the R-CHOP regimen, patients with FL/DLBCL showed similar overall survival to those with DLBCL.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Sina Abdollahi, Seyedeh Zahra Dehghanian, Liang-Yi Hung, Shiang-Jie Yang, Dao-Peng Chen, L. Jeffrey Medeiros, Jung-Hsien Chiang, Kung-Chao Chang
Summary: The study found that genes associated with migration/invasion were more prevalent in DLBCL cases involving effusions. Validation in DLBCL cell lines and clinical samples revealed that overexpression of HDAC1 and MDM2 was correlated with lymphomatous effusions, with HDAC1 overexpression linked to the poorest prognosis. The findings suggest a mechanistic association between DLBCL with effusions and the TP53-MDM2 pathway and HDAC-related chromatin remodeling mechanisms.
BIOMARKER RESEARCH
(2021)
Article
Oncology
Wendan Xu, Philipp Berning, Tabea Erdmann, Michael Grau, Nardjas Bettazova, Myroslav Zapukhlyak, Fabian Frontzek, Corinna Kosnopfel, Peter Lenz, Michael Grondine, Brandon Willis, James T. Lynch, Pavel Klener, Stephan Hailfinger, Simon T. Barry, Georg Lenz
Summary: This study reveals that certain subtypes of DLBCL are dependent on PI3K β/δ signaling and demonstrates that combined targeting of PI3K β/δ and mTOR is effective in overcoming resistance to PI3K β/δ inhibition.
Article
Oncology
Jan Duerig, Jens Uhlig, Anke Gerhardt, Markus Ritter, Gunnar Hapke, Joerg Hessling, Peter Staib, Frieder Wolff, Katja Krumm, Ludwig Fischer von Weikersthal
Summary: Subcutaneous rituximab has demonstrated effectiveness and safety in patients with follicular lymphoma and diffuse large B cell lymphoma. Patient and nurse satisfaction with subcutaneous administration was high.
Review
Hematology
Eliza A. Hawkes, Allison Barraclough, Laurie H. Sehn
Summary: Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, has a good prognosis in limited-stage DLBCL (LS-DLBCL) patients. Recent studies have provided new insights and strategies for the treatment of LS-DLBCL, including the use of PET scans and clinical trials. However, there is currently no standard definition for LS-DLBCL, and treatment strategies vary across studies, posing challenges in interpretation.